加载中
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
收盘时
US$17.80
−US$0.82 · -4.40%
盘后
US$18.00
+US$0.20 · +1.12%
10月12日 18:38 ET
盘中时间采用ET。市场数据可能有所延迟。
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
日内区间
当前US$17.80
52周区间
当前US$17.80
盘中时间采用ET。市场数据可能有所延迟。
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
日内区间
当前US$17.80
52周区间
当前US$17.80
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 10.29亿 USD | 6.27亿 USD | 2.85亿 USD | 1.17亿 USD | 6882.6万 USD |
| 销货成本 | 4.08亿 USD | 2.35亿 USD | 1.44亿 USD | 6536.3万 USD | — |
| 毛利 | 6.21亿 USD | 3.93亿 USD | 1.41亿 USD | 5164.2万 USD | 6882.6万 USD |
| 研究与开发 | 4.15亿 USD | 4.14亿 USD | 3.82亿 USD | 3.36亿 USD | 3.13亿 USD |
| 销售、一般及管理费用 | 3.42亿 USD | 2.84亿 USD | 2.01亿 USD | 1.74亿 USD | 1.5亿 USD |
| 营业费用 | 7.57亿 USD | 6.96亿 USD | 5.8亿 USD | 5.07亿 USD | 4.61亿 USD |
| 利息收入 | 4010万 USD | 6120.4万 USD | 5448.7万 USD | 818.2万 USD | 97.1万 USD |
| 利息支出 | 2140万 USD | 2161.5万 USD | 2179.4万 USD | 1079.6万 USD | 90万 USD |
| 折旧和摊销 | 2890万 USD | 2335.9万 USD | 2045.1万 USD | 1839.2万 USD | 1391.7万 USD |
| 营业利润 | −1.37亿 USD | −3.03亿 USD | −4.39亿 USD | −4.56亿 USD | −3.92亿 USD |
| 净利润 | −2.97亿 USD | −1.77亿 USD | −5.18亿 USD | −4.46亿 USD | −4.04亿 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$61.00
上涨空间 242.70%报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB2370.29万0.22%108.2亿 USD0.44%US$204.26-1.08%
iShares Core MSCI Emerging Markets ETFIEMG1555.35万0.01%1602.49亿 USD0.09%US$80.63-0.95%
Invesco Biotechnology & Genome ETFPBE1023.44万2.43%4.22亿 USD0.59%US$96.405-0.51%
iShares Core MSCI China ETF2801.HK687.01万0.06%121.2亿 HKD0.20%HK$23.34+0.26%
Tema Oncology ETFCANC379.86万1.85%2.05亿 USD0.99%US$40.5781-0.50%
iShares Core MSCI Asia ex Japan ETF3010.HK362.01万0.01%338.44亿 HKD0.28%HK$89.00+1.09%
iShares MSCI Emerging Markets ETFEEM345.52万0.01%309.79亿 USD0.72%US$66.15-0.97%
iShares MSCI China ETFMCHI340.01万0.06%60.07亿 USD0.59%US$52.15-0.76%iShares Biotechnology ETFIBBiShares Core MSCI Emerging Markets ETFIEMGInvesco Biotechnology & Genome ETFPBEiShares Core MSCI China ETF2801.HKTema Oncology ETFCANCiShares Core MSCI Asia ex Japan ETF3010.HKiShares MSCI Emerging Markets ETFEEMiShares MSCI China ETFMCHIAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
